ARCO

Arco Therapeutics is a Cambridge-based biotechnology company focused on developing a new class of small molecule drugs that target protein-protein interactions (PPIs). The company leverages a proprietary platform to identify and modulate previously undruggable PPI targets, which are critical in various disease pathways but have historically been difficult to address with traditional small molecules. Backed by prominent investors like F-Prime Capital and Eight Roads Ventures, Arco aims to expand the reach of small molecule therapeutics into complex biological networks. Their initial focus is on high-need therapeutic areas, particularly oncology and immunology, where PPI modulation can offer novel mechanisms of action.